Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics

Adam J Nelson; Lisa A Kaltenbach; Darren K McGuire; Monica Levya; Hussein R Al-Khalidi; Laura Webb; Renato D Lopes; Rodica Pop-Busui; Matthew A Cavender; Vanita R Aroda; Melissa L Magwire; Caroline R Richardson; Ildiko Lingvay; Julienne K Kirk; Ambarish Pandey; Tanya Gaynor; Jonathan Pak; Alana Washington; Cagri Senyucel; Jennifer B Green; Christopher B Granger; Neha J Pagidipati

doi:10.1016/j.ahj.2024.12.006

Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics

Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.12.006. Online ahead of print.

Authors

Adam J Nelson¹, Lisa A Kaltenbach², Darren K McGuire³, Monica Levya², Hussein R Al-Khalidi², Laura Webb², Renato D Lopes², Rodica Pop-Busui⁴, Matthew A Cavender⁵, Vanita R Aroda⁶, Melissa L Magwire⁷, Caroline R Richardson⁸, Ildiko Lingvay⁹, Julienne K Kirk¹⁰, Ambarish Pandey⁹, Tanya Gaynor¹¹, Jonathan Pak¹¹, Alana Washington¹², Cagri Senyucel¹², Jennifer B Green², Christopher B Granger², Neha J Pagidipati²

Affiliations

¹ Duke Clinical Research Institute, Durham, NC; University of Adelaide, South Australia, Australia. Electronic address: [email protected].
² Duke Clinical Research Institute, Durham, NC.
³ University of Texas Southwestern Medical Center, Dallas, TX; Parkland Health, Dallas, TX.
⁴ University of Michigan Medical School, Ann Arbor, MI.
⁵ University of North Carolina, Chapel Hill, NC.
⁶ Brigham and Women's Hospital, Boston, MA.
⁷ St Luke's Health System, Kansas City, MO.
⁸ Warren Alpert Medical School of Brown University, Providence, RI.
⁹ University of Texas Southwestern Medical Center, Dallas, TX.
¹⁰ Wake Forest University School of Medicine, Winston Salem, NC.
¹¹ Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.
¹² Eli Lilly and Company, Indianapolis, IN.

PMID: 39716628
DOI: 10.1016/j.ahj.2024.12.006

Abstract

SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) but are underused in clinical practice. The COORDINATE-Diabetes randomized clincal trial evaluated a multi-faceted intervention to increase the use of evidence-based therapies for reducing cardiovascular risk among participants with diabetes and atherosclerotic cardiovascular disease. This analysis reports the discontinuation rate of SGLT-2i and GLP-1RA in follow up and summarises the clinician-reported reasons underlying these decisions.

Keywords: discontinuation; glucagon-like peptide 1 receptor agonist; persistence; sodium glucose cotransporter 2 inhibitor; type 2 diabetes mellitus.